drugset / Trial / NCT05938075
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
Phase 1
Completed
130 enrolled
Vaccine Company, Inc.
Medical Research Council, South Africa · collab
RandomizedSequentialOpen-labelPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in adults.
Timeline
- Start
- 2023-08-04
- Primary completion
- 2024-07-25
- Completion
- 2024-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VXCO-100 | Vaccine | — | Intramuscular |